Broker gets clean bill of health from IDS

May 30 2009 by Iain Laing, The Journal

INVESTMENT manager Brewin Dolphin Investment Banking has been appointed as sole broker to North East medical technology company Immunodiagnostic Systems (IDS).

The Newcastle broker will be the advisor to Boldon-based IDS, a leading producer of diagnostic testing kits for the clinical and research markets.

IDS has grown rapidly in recent years and the company is now recognised as a global leader in specialist bone diagnostics. The company successfully made two substantial acquisitions in 2007 in continental Europe.

As a result, IDS is now entering a new and much larger global market for its products and anticipated accelerated growth. The company sells its products in over 25 countries, with direct subsidiaries in the major markets.

Graeme Summers, head of investment banking at Brewin Dolphin, said: “I am delighted to announce that we’ve been appointed broker to such a high quality company with very exciting growth prospects.

“It not only further boosts our presence in the healthcare sector, but is also testament to the longevity and expertise of the team here at Brewin Dolphin Investment Banking – in particular Chris Glasper, assistant director of equity research, and Andrew Emmott, director of corporate finance.

“Healthcare was one of the sectors we chose to focus on when we announced our ambition to become the UK’s leading corporate adviser and institutional broker for growth companies. Since then we have made significant progress and now work with over 15 companies in the sector.”

IDS chief executive Dr Roger Duggan said: “We are impressed by the team’s in-depth knowledge of the healthcare sector.”